Keene & Associates Inc. Has $290,000 Stock Position in Smith & Nephew plc (NYSE:SNN)

Keene & Associates Inc. lifted its stake in Smith & Nephew plc (NYSE:SNN) by 13.2% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,700 shares of the medical equipment provider’s stock after buying an additional 1,360 shares during the period. Keene & Associates Inc.’s holdings in Smith & Nephew were worth $290,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. National Bank of Canada FI lifted its holdings in shares of Smith & Nephew by 36.0% during the fourth quarter. National Bank of Canada FI now owns 1,967 shares of the medical equipment provider’s stock valued at $53,000 after acquiring an additional 521 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in Smith & Nephew by 75.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,227 shares of the medical equipment provider’s stock valued at $33,000 after purchasing an additional 526 shares during the last quarter. Argonautica Private Wealth Management Inc. boosted its position in Smith & Nephew by 6.3% in the second quarter. Argonautica Private Wealth Management Inc. now owns 10,244 shares of the medical equipment provider’s stock valued at $254,000 after buying an additional 605 shares in the last quarter. Inspire Advisors LLC grew its stake in Smith & Nephew by 3.0% during the second quarter. Inspire Advisors LLC now owns 22,286 shares of the medical equipment provider’s stock worth $552,000 after buying an additional 639 shares during the last quarter. Finally, Rhumbline Advisers increased its holdings in shares of Smith & Nephew by 8.6% during the second quarter. Rhumbline Advisers now owns 10,365 shares of the medical equipment provider’s stock worth $257,000 after buying an additional 819 shares in the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.

Wall Street Analysts Forecast Growth

SNN has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft began coverage on Smith & Nephew in a research report on Wednesday, July 24th. They set a “buy” rating on the stock. UBS Group raised Smith & Nephew from a “neutral” rating to a “buy” rating in a report on Wednesday, June 5th. Finally, StockNews.com raised shares of Smith & Nephew from a “buy” rating to a “strong-buy” rating in a report on Monday, August 5th. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy”.

Smith & Nephew Price Performance

Shares of SNN stock opened at $31.50 on Monday. Smith & Nephew plc has a 12 month low of $21.52 and a 12 month high of $31.72. The company has a current ratio of 2.51, a quick ratio of 1.11 and a debt-to-equity ratio of 0.63. The stock has a 50-day moving average price of $29.79 and a 200 day moving average price of $26.94.

Smith & Nephew Increases Dividend

The firm also recently declared a dividend, which will be paid on Friday, November 8th. Stockholders of record on Friday, October 4th will be given a dividend of $0.288 per share. This is a boost from Smith & Nephew’s previous dividend of $0.24. The ex-dividend date of this dividend is Friday, October 4th.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.